Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Jeffrey Dierks Sells 1,123 Shares

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 1,123 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.00, for a total value of $44,920.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Jeffrey Dierks also recently made the following trade(s):

• On Wednesday, January 15th, Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock. The shares were sold at an average price of $37.01, for a total transaction of $388,864.07.
• On Tuesday, October 29th, Jeffrey Dierks sold 21,496 shares of Harmony Biosciences stock. The shares were sold at an average price of $40.47, for a total transaction of $869,943.12.

Harmony Biosciences Price Performance

Shares of HRMY stock opened at $40.46 on Wednesday. The firm has a market cap of $2.31 billion, a price-to-earnings ratio of 19.18, a PEG ratio of 0.54 and a beta of 0.78. Harmony Biosciences Holdings, Inc. has a 12 month low of $28.14 and a 12 month high of $41.61. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The stock has a 50-day moving average price of $34.46 and a 200 day moving average price of $34.96.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company had revenue of $186.00 million during the quarter, compared to analysts’ expectations of $184.07 million. During the same quarter in the previous year, the company earned $0.63 EPS. Harmony Biosciences’s revenue was up 16.0% on a year-over-year basis. Research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Mizuho lifted their price objective on Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday, October 10th. HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of Harmony Biosciences in a research note on Thursday, January 16th. Cantor Fitzgerald lifted their price target on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Oppenheimer restated an “outperform” rating and set a $59.00 price target (up from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Finally, Raymond James reiterated an “outperform” rating and issued a $40.00 price objective on shares of Harmony Biosciences in a research report on Thursday, October 10th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $55.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in HRMY. Dimensional Fund Advisors LP increased its holdings in Harmony Biosciences by 13.3% in the second quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock valued at $28,871,000 after purchasing an additional 112,197 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Harmony Biosciences by 27.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock worth $26,416,000 after purchasing an additional 140,690 shares during the period. Millennium Management LLC grew its holdings in shares of Harmony Biosciences by 51.6% in the 2nd quarter. Millennium Management LLC now owns 307,420 shares of the company’s stock valued at $9,275,000 after buying an additional 104,691 shares during the period. Marshall Wace LLP increased its position in shares of Harmony Biosciences by 145.4% in the 2nd quarter. Marshall Wace LLP now owns 305,612 shares of the company’s stock valued at $9,220,000 after buying an additional 181,092 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Harmony Biosciences by 68.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company’s stock worth $9,217,000 after buying an additional 93,622 shares during the period. Institutional investors and hedge funds own 86.23% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.